间歇性跛行患者贫血的患病率、特征及临床影响
该回顾性研究分析了403例间歇性跛行患者,发现贫血患病率为17.6%,以轻度正常细胞正常色素性贫血为主,77.8%的贫血患者未接受治疗。校正后贫血与主要不良心血管事件(aHR=2.96)和全因死亡(aHR=4.59)风险升高相关,但与肢体丢失结局无关。
要点
- 间歇性跛行患者中贫血患病率约17.6%,以轻度贫血为主。
- 77.8%的贫血患者未接受任何治疗,存在显著治疗缺口。
- 贫血与MACE和全因死亡风险升高独立相关。
核心结论
- 贫血影响约五分之一的间歇性跛行患者,且治疗缺口显著,77.8%未接受治疗。
- 贫血与主要不良心血管事件和全因死亡风险升高相关,但与肢体丢失相关结局无关。
研究设计与样本
- 回顾性分析2023年3个月内就诊于三级血管门诊的403例连续间歇性跛行患者。
- 主要结局包括贫血患病率、特征、治疗模式及24个月临床结局。
主要发现
- 307例(76.2%)接受了贫血检查,其中54例(17.6%)确诊贫血,77.8%为男性。
- 轻度贫血48例(88.9%),中度贫血6例(11.1%),未见重度贫血。
- 正常细胞正常色素性贫血占79.6%(43例),小细胞低色素性贫血占14.8%(8例),差异有统计学意义(P < 0.001)。
- 仅11.1%的贫血患者发现缺铁,仅33.3%的贫血患者接受了铁代谢检查。
- 校正后贫血与MACE(aHR=2.96,95%CI 1.23-7.08;P=0.015)和全因死亡(aHR=4.59,95%CI 1.33-15.81;P=0.016)相关。
关键数值与推荐
- 贫血治疗与跛行改善的非显著趋势:校正后OR=4.82,95%CI 0.96-24.22;P=0.056。
- 双侧跛行在贫血患者中更常见(66.7% vs. 52.2%,P=0.052),但未达统计学显著性。
临床怎么用
- 对间歇性跛行患者应常规筛查贫血,并完善铁代谢检查以明确病因。
- 贫血患者需加强心血管风险监测与管理,警惕MACE和死亡风险升高。
- 未来需前瞻性随机对照试验评估贫血治疗策略的疗效。
局限性
- 回顾性设计,可能存在选择偏倚和信息偏倚。
- 仅33.3%的贫血患者接受铁代谢检查,缺铁患病率可能被低估。
- 贫血治疗与跛行改善的关联未达统计学显著性,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence and clinical impact of anemia in patients with intermittent claudication (IC) is unclear, and consequently, evidence-based treatment strategies are ambiguous. This study investigated anemia characteristics and clinical outcomes in patients with intermittent claudication. METHODS: A retrospective analysis of 403 consecutive patients with IC attending a tertiary vascular clinic over 3 months in 2023 was conducted. Primary outcomes included anemia prevalence, characterization, treatment patterns, and 24-month clinical outcomes: symptom improvement following anemia treatment, progression to chronic limb-threatening ischemia , major amputation, major adverse cardiovascular events (MACEs), and all-cause mortality. RESULTS: Among 403 patients, 307 (76.2%) underwent anemia investigation, which identified anemia in 54 cases (17.6%), of whom 77.8% were male. Most patients had mild anemia (n = 48, 88.9%), with the remainder having moderate anemia (n = 6, 11.1%). Severe anemia was not observed in this cohort. Normocytic normochromic anemia predominated (79.6%, n = 43), and 14.8% (n = 8) had microcytic hypochromic anemia (P < 0.001), while iron deficiency was identified in only 11.1%, although only 33.3% of anemic patients underwent iron studies. Treatment gaps were substantial with 77.8% did not receive any anemia treatment. After adjustment for interval revascularization, anemia treatment showed a nonsignificant trend toward higher claudication improvement among anemic patients (adjusted odds ratio 4.82, 95% confidence interval [CI] 0.96-24.22; P = 0.056). Bilateral claudication was more frequent in anemic than nonanamic patients (66.7% vs. 52.2%, P = 0.052), but this did not reach statistical significance. Adjusted Cox models showed that anemia was associated with MACE (adjusted hazard ratio [HR] = 2.96, 95% CI 1.23-7.08; P = 0.015) and all-cause mortality (adjusted HR = 4.59, 95% CI 1.33-15.81; P = 0.016), but not limb loss-related outcomes. CONCLUSION: Anemia affects approximately one in five patients with IC and represents a significant treatment gap, with 77.8% receiving no therapy, despite anemia was associated with higher MACE and mortality risk. A prospective randomized controlled trial evaluating the efficacy of anemia treatment strategies in this cohort may help to improve understanding and guide clinical management.
引用
- Hong JS, Loy G, Sivaharan A, et al. Anemia Prevalence, Characterization, and Clinical Impact in Intermittent Claudication. Ann Vasc Surg. 2026. PMID: 42697327. doi:10.1016/j.avsg.2026.08.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。